April 23 Quick Takes: Hansoh, NiKang partner for antiviral; plus Jakafi, Avastin, EpimAb-QIMR, ProThera-Takeda

Jakafi meets in Phase III for GvHD; low dose Avastin for retinopathy of prematurity

Hansoh gains China rights to NiKang antiviral
Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692) gained rights to develop and commercialize NKT-1992 from NiKang Therapeutics Inc. for viral diseases in Greater China.

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE